Jenna Adams
Family · Portsmouth, NHNPI 1235687658
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.3% of the total across 158 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 11.9% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 158 payments — averaging $26.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$498
- Bayer$397
- AbbVie$384
- Acadia Pharmaceuticals Inc$257
- Pfizer$235
- Lundbeck LLC$235
- plus $2K from 24 others
What the payments were for
- Food & beverage$3,98095%
- Education$1945%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 21 | $498 |
| Bayer | 10 | $397 |
| AbbVie | 13 | $384 |
| Acadia Pharmaceuticals Inc | 7 | $257 |
| Pfizer | 13 | $235 |
| Lundbeck LLC | 14 | $235 |
| Phathom Pharmaceuticals, Inc. | 8 | $218 |
| Otsuka America Pharmaceutical, Inc. | 3 | $215 |
| Teva Pharmaceuticals USA, Inc. | 6 | $209 |
| Merck | 6 | $168 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $151 |
| Johnson & Johnson(2 entities) | 6 | $144 |
| Biohaven Pharmaceuticals, Inc. | 6 | $140 |
| Astellas Pharma US Inc | 3 | $129 |
| QOL Medical, LLC | 3 | $116 |
| Sunovion Pharmaceuticals Inc. | 6 | $94 |
| AstraZeneca(2 entities) | 4 | $84 |
| CMP Pharma, Inc. | 3 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $64 |
| Lilly USA, LLC | 3 | $56 |
| Amarin Pharma, Inc. | 3 | $50 |
| Arcutis Biotherapeutics, Inc. | 2 | $47 |
| Aimmune Therapeutics, Inc. | 2 | $43 |
| Celltrion USA Inc. | 2 | $39 |
| Neurelis, Inc. | 1 | $28 |
| Verona Pharma, Inc. | 1 | $28 |
| Gilead | 1 | $24 |
| Novartis | 1 | $21 |
| Dexcom, Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,175 in reported general payments places this provider in the 95th percentile of 713 family providers in New Hampshire.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 50 | $30,567 |
| EliquisApixaban | 55 | $16,690 |
| MyrbetriqMirabegron | 59 | $13,762 |
| OzempicSemaglutide | 12 | $13,107 |
| RexultiBrexpiprazole | 15 | $10,906 |
| JardianceEmpagliflozin | 24 | $7,301 |
| Incruse ElliptaUmeclidinium Bromide | 18 | $6,807 |
| VascepaIcosapent Ethyl | 21 | $3,841 |
| LantusInsulin Glargine,hum.Rec.Anlog | 37 | $2,876 |
| Fentanyl | 22 | $2,754 |
| Sevelamer Carbonate | 16 | $2,187 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 11 | $2,161 |
| LevemirInsulin Detemir | 17 | $2,044 |
| HumalogInsulin Lispro | 26 | $1,916 |
| Budesonide | 17 | $1,761 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Humalog | $56 | $32,48476 claims |
| PfizerEliquis | $235 | $16,69055 claims |
| Novo NordiskOzempic, Levemir | $498 | $15,15129 claims |
| Astellas Pharma US IncMyrbetriq | $129 | $13,76259 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $215 | $10,90615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 713 family providers in New Hampshire.
Other family in Portsmouth
- Tara Delle ChiaieHampton$548K
- Wendy WrightAmherst$447K
- Richard CareyNashua$51K
- Summer BellDerry$16K
- Laura HudsonDover$14K
- Debra KrisonNorth Hampton$13K
- Michelle WhiteBedford$9K
- Brant OliverConcord$9K
- Cassandra CavanaughDover$9K
- Scott SabishConcord$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.